Patent · US Active

Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse

US10111896B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignees

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
UNIVERSITE DE PARIS DESCARTES · FR
Moraine Corporation · FR
UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
UNIVERSITÉ PARIS-SUD · DE
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

Ivan Cruz-Moura · Paris, FR
Olivier Hermine · Palaiseau, FR
Etienne Paubelle · Paris, FR
Michael Dussiot · Paris, FR
Thiago Trovati Maciel · Paris, FR
Florence Zylbersztejn · Paris, FR

Key dates

Filing date	Jun 19, 2015
Grant date	Oct 30, 2018
Priority date	—
Expiry date	Jun 19, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.